ArticleBritish journal of clinical pharmacology2020
Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury.
Article in British journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Characteristic histopathology of phenprocoumon-induced liver injury: correlation with clinical presentation and outcome.Virchows Archiv : an international journal of pathology · 2026Article
- Metamizole: Indications and Risks.Deutsches Arzteblatt international · 2026Review
- To use or not to use: Safety of selected painkillers in patients with chronic liver diseases.Clinical and experimental hepatology · 2025Review
- Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance.Arthritis research & therapy · 2025Article
- 16. Pain in chronic pancreatitis.Pain practice : the official journal of World Institute of Pain · 2025Review
- Drug-Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- Article
- Discovering the inhibition of YAP/TEAD Hippo signaling pathway via new pyrazolone derivatives: synthesis, molecular docking and biological investigations.Scientific reports · 2024Article
- Metamizole in the Management of Musculoskeletal Disorders: Current Concept Review.Journal of clinical medicine · 2024Review
- Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.International journal of molecular sciences · 2023Review
- A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis.Deutsches Arzteblatt international · 2022Article
- Review
- Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users.Drug safety · 2021Article
- Metamizole Has Been Overlooked as a Trigger for Acute Liver Injury and Acute Liver Failure.Deutsches Arzteblatt international · 2020Article
- Liver injury associated with the analgetic drug metamizole.British journal of clinical pharmacology · 2020Article
- Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury.British journal of clinical pharmacology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
aimsDrug-induced liver injury (DILI) is a heterogenous entity leading to liver damage. We have analysed the frequency, biochemical and histological patterns and clinical courses of DILI cases due to metamizole at our tertiary care centre in Hamburg, Germany.
methodsConsecutive patients with DILI who presented to our clinic were analysed retrospectively. Causes of acute hepatitis other than DILI were excluded.
resultsIn total, 154 DILI cases were admitted to our centre from 2008 to 2017. After phenprocoumon, metamizole was the second most frequent putative agent causing DILI (23 of all 154 DILI cases, 14,9%). The biochemical pattern on admission of metamizole-induced DILI cases was hepatocellular with median levels of alanine transaminase (779 U/L, 64-3532 U/L) by far exceeding median alkaline phosphatase levels (131 U/L, 42-578 U/L). In 17 of the 23 cases (74%) liver biopsy was performed. Moderate to severe inflammatory histological activity and severe centrilobular necrosis (>30%) was present in 76.5 and 35.3%, respectively. Metamizole was involved in 2 DILI cases progressing to acute liver failure, then receiving liver transplantation and still alive at time of assessment. Our data were supported by re-exposure in 4 patients. Furthermore, a database search for metamizole-induced liver injury in the European Medicines Agency's database identified about 300 reports on suspected metamizole-induced DILI in Europe.
conclusionElevation of liver enzymes or acute liver failure are not mentioned in the German drug label of metamizole as potential side effects. Our study reveals that in Germany and Europe, metamizole is a frequent and underrated agent causing DILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.